On this week’s episode of VJOncology podcasts, we explore advances in personalized approaches towards prostate cancer. Join Anis Hamid of Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Keizman of Ichilov-Sourasky Medical Center, Tel-Aviv, Israel, Susan Halabi of Duke Cancer Institute, Durham, NC, and Andrew Armstrong of Duke University Medical Center, Durham, NC, as they discuss predictors of benefit for intensified therapy in metastatic hormone sensitive prostate cancer, a circulating tumor DNA (ctDNA)-based prognostic model in metastatic castration-resistant prostate cancer, and the association between tumor genetics, smoking and prostate cancer outcomes.